Cytovance Biologics has announced that the United States Food & Drug Administration (FDA) has concluded a successful Pre-License Inspection at Cytovance with no 483 observations.  The focus of the five-day PLI was quality systems, facilities, maintenance programs and the manufacturing of client’s candidate product. “We are very pleased with the result of the FDA inspection demonstrating Cytovance’s unwavering commitment to quality and patient safety,” sta...